Market Analysis & Strategy - The market experienced seasonal choppiness, prompting a debate on whether it's a healthy reset or a sign of fragility [1][2] - The current market weakness is viewed as a buying opportunity, contingent on continued profit growth for the remainder of the year and into next year [5] - Consensus earnings forecasts have been inching up, providing support to the market [6] AI Theme & Tech Sector - There's a reevaluation of the AI theme, questioning if companies have been over-credited prematurely [6] - Despite recent negative headlines, the capex story for generative AI is still growing, with hyperscalers increasing their investments [8][9] - AI-related stocks are expected to remain leaders in the market as long as the earnings and capex stories continue to grow [10] Economic Indicators & Sector Rotation - Small caps have shown better performance recently, particularly in the industrial sector, driven by improving news in manufacturing [12][13] - A rotation or rebalancing in the market can continue even if tech remains a cornerstone leader [13][14]

Despite the recent rotation out of tech, my next guest still sees opportunity there. So, joining me now is Matt Mskin, co-chief investment strategist at Manu Life, John Hancock Investments. Matt, it's great to have you on.And let's start right there. What do you think of stocks at these levels and and where do you think we go from here. Yeah, Morgan, today's a day that reminds you that the market was really looking forward to some rate cuts.And the thought that the economy is actually accelerating here into ...

Core Insights - Jack Henry & Associates (JKHY) reported fourth-quarter fiscal 2025 GAAP earnings of $1.75 per share, exceeding the Zacks Consensus Estimate by 19.9% and reflecting a year-over-year increase of 26.4% [1][9] - The company's revenues for the quarter reached $615.4 million, surpassing the Zacks Consensus Estimate by 1.6% and showing a year-over-year growth of 9.9% [1][9] - Non-GAAP revenues, after adjusting for deconversion revenues of $20.5 million, were $594.9 million, representing a 7.5% increase year over year [1] Revenue Breakdown - Revenues from Services and Support, accounting for 57.1% of total revenues, were $351.2 million, up 10.9% year over year, driven by growth in data processing and hosting revenues [3] - Processing revenues, which made up 42.9% of total revenues, were $264.1 million, an increase of 8.6% year over year, primarily due to growth in card, transaction, and digital payment processing revenues [4] - Core segment revenues were $189.7 million, up 10.3% year over year, while Payments revenues rose 7.9% to $229.3 million, and Complementary revenues increased 12.9% to $175.1 million [5] Profitability Metrics - Adjusted EBITDA for the fourth quarter was $189.2 million, reflecting a year-over-year increase of 10.9%, with an adjusted EBITDA margin expanding by 100 basis points to 31.8% [6] - Adjusted operating income rose 14.8% year over year to $137.8 million, with the adjusted operating margin increasing by 150 basis points to 23.2% [6] Balance Sheet and Cash Flow - As of June 30, 2025, the company's cash and cash equivalents stood at $102 million, a significant increase from $39.9 million as of March 31, 2025 [7] Future Guidance - For fiscal 2026, Jack Henry & Associates has initiated GAAP revenue guidance of $2.50-$2.48 billion, with non-GAAP revenues expected to be $2.48-$2.46 billion [8] - The Zacks Consensus Estimate for revenues is $2.53 billion, indicating a year-over-year growth of 6.7% [8] - GAAP earnings are projected to be in the range of $6.44-$6.32 per share, with a year-over-year increase of 5.1% expected [10]

Core Insights - American Express Company (AXP) has outperformed the S&P 500 and broader industry with a 24.3% gain over the past year, although it lagged behind larger peers Visa Inc. (27.7%) and Mastercard Incorporated (25.1%) [1][5] - The company's strong brand and affluent customer base have provided resilience against macroeconomic volatility, maintaining its reputation as a quality investment [2][21] - AXP currently trades below the Wall Street average price target of $321.38, indicating a limited upside of 4.7% from current levels [3][5] Financial Performance - AXP's forward P/E ratio stands at 18.43X, which is below the industry average of 20.56X but above its five-year median of 17.03X, suggesting it may be slightly overvalued historically [8][9] - The company reported a second-quarter interest income of $6.3 billion, reflecting an 8% year-over-year increase, supported by its unique business model as both a card issuer and a bank [12] - Network volumes rose 7% to $472 billion in the second quarter, driven by resilient consumer spending among its affluent customer base [13] Balance Sheet Strength - AXP holds $57.9 billion in cash and cash equivalents with only $1.5 billion in short-term borrowing, indicating a strong balance sheet [14] - The total assets increased to $295.6 billion from $271.5 billion at the end of 2024, with a net debt-to-capital ratio of 1.91%, significantly lower than the industry average of 16.11% [14] Growth Estimates - Analysts project a 14.3% year-over-year increase in AXP's earnings for 2025, with 2026 earnings expected to grow by 13.7% [16] - Revenue estimates for 2025 and 2026 indicate growth of 8.3% and 8.1%, respectively, with a solid track record of surpassing earnings expectations [16][17] Risks and Challenges - AXP is more exposed to travel and entertainment spending, which can decline sharply during economic downturns, making it vulnerable despite its affluent customer base [18][22] - Rising operating costs have been a concern, with expenses increasing significantly over the past few years, which could pressure margins [19] - The company's domestic focus compared to Visa and Mastercard's global expansion may limit its adaptability to emerging payment trends [20][22]

Core Insights - Phibro Animal Health (PAHC) shares have increased by 76.4% over the past year, significantly outperforming the industry growth of 4.9% and the S&P 500's 16% gain [1][8] - The company is currently ranked 2 (Buy) by Zacks, indicating strong fundamentals and growth potential [1] Company Overview - Phibro, based in New Jersey, offers a wide range of products for food animals, including poultry, swine, beef, dairy cattle, and aquaculture, as well as ingredients for personal care and industrial sectors [2] - The company is focusing on expanding its product offerings in the companion animal sector [2] Growth Drivers - The surge in PAHC's share price is attributed to a strong sales recovery in its Mineral Nutrition and Performance Products segments, with Mineral Nutrition growing by 4% year over year and Performance Products increasing by 28% year over year [3] - The recent acquisition of medicated feed additive products and certain water-soluble products from Zoetis Inc. has expanded Phibro's Animal Health product portfolio [3] International Market Contribution - Approximately 40% of Phibro's total revenues come from international markets, including high-growth regions such as Brazil, China, India, and Southeast Asia [4] Financial Health - Phibro has a solid financial position, with a low short-term payable debt of $16 million compared to total cash and short-term investments of $70.4 million [5] - The company reported an operating profit of $33.4 million for the fiscal third quarter, reflecting a 67.8% year-over-year increase and an expansion of the operating margin by 204 basis points [5] Earnings Estimates - Phibro's earnings per share (EPS) are projected to increase by 71.4% to $2.04 for fiscal 2025 and by 12.7% to $2.30 for fiscal 2026 [9] - Revenues are expected to grow by 25.7% to $1.28 billion in fiscal 2025 and reach $1.41 billion in fiscal 2026, indicating a 10.1% increase [9]

Core Viewpoint - IDACORP Inc. (IDA) is positioned as a strong investment option in the utility sector due to its strategic investments, customer growth, effective cost management, and focus on clean energy production [1] Growth Projections & Surprise History - The Zacks Consensus Estimate for IDA's 2025 earnings per share (EPS) has increased by 0.3% to $5.83 over the past 60 days [2] - The 2025 sales estimate stands at $1.85 billion, reflecting a year-over-year increase of 1.6% [2] - IDA's long-term earnings growth rate is projected at 8.13%, with an average earnings surprise of 3.9% over the last four quarters [2] Liquidity - IDACORP's current ratio is 1.45, surpassing the industry average of 0.85, indicating sufficient short-term assets to cover liabilities [3] Debt Position - The total debt to capital ratio for IDA is 50.29%, which is better than the industry average of 59.75% [4] - The time-to-interest earned ratio is 2.7, demonstrating the company's capability to meet future interest obligations [4] Dividend History - IDA has consistently increased shareholder value through regular dividends, currently paying 86 cents per share, leading to an annualized dividend of $3.44 and a dividend yield of 2.76% [5] Systematic Investments - The company invested $943 million in 2024 and anticipates capital expenditures of $1-$1.1 billion in 2025, $1.25-$1.35 billion in 2026, and $3.1-$3.6 billion from 2027 to 2029 [6] Rising Customer Base - IDA's customer base grew by 2.5% year-over-year as of June 30, 2025, driven by improving economic conditions in its service areas [7][8] Stock Price Performance - Over the past three months, IDA's shares have increased by 6.2%, contrasting with a 0.6% decline in the industry [9]

Core Insights - Warren Buffett was a net seller of stocks for the 11th consecutive quarter in Q2 2025, but he also invested $3.9 billion in 12 stocks, including three new positions [1][3] - Half of the purchases involved increasing existing positions, notably in Chevron and Lennar Class B [3][4] - New positions were initiated in Allegion, Lamar Advertising, and UnitedHealth Group [5] Investment Highlights - Heico is the biggest winner among Buffett's Q2 purchases, closely followed by Allegion and Nucor [6] - Lennar and D.R. Horton have the lowest valuations based on forward price-to-earnings ratios [6] - UnitedHealth Group has the most attractive price-to-earnings-to-growth (PEG) ratio at 1.24 among the 12 stocks [7] Growth Projections - Nucor is projected to have nearly 32.5% earnings growth next year, with Chevron at around 24.4% [8] - Constellation Brands is favored by analysts, with a 12-month price target reflecting an upside potential of around 22% [9] Dividend Yields - Lamar Advertising has the highest forward dividend yield at 5.09%, followed by Chevron at 4.39% [10] Best Investment Choice - UnitedHealth Group is highlighted as the best investment among the 12 stocks, with a significant investment of approximately $1.57 billion from Buffett [11] - Despite challenges such as higher medical costs and investigations into Medicare billing practices, these issues are believed to be reflected in the current share price [12]

Core Viewpoint - Growth investors are increasingly focused on identifying stocks with above-average financial growth, which can lead to solid returns, but finding such stocks is challenging due to inherent volatility and risks [1] Company Summary - Kamada (KMDA) is identified as a promising growth stock, supported by a favorable Growth Score and a top Zacks Rank [2] - The historical EPS growth rate for Kamada is 0.9%, but projected EPS growth for this year is expected to be 50.7%, significantly higher than the industry average of 18.4% [4] - Kamada has an asset utilization ratio (sales-to-total-assets ratio) of 0.46, outperforming the industry average of 0.31, indicating higher efficiency in generating sales [5] - The company's sales are projected to grow by 12.4% this year, compared to an industry average of 0% [6] - There has been a positive trend in earnings estimate revisions for Kamada, with the Zacks Consensus Estimate for the current year increasing by 14.1% over the past month [8] - Kamada holds a Growth Score of B and a Zacks Rank of 2, positioning it well for potential outperformance in the market [10]

Company Overview - Investar (ISTR) is headquartered in Baton Rouge and operates in the Finance sector [3] - The stock has experienced a price change of 0.23% since the beginning of the year [3] Dividend Information - Investar currently pays a dividend of $0.11 per share, resulting in a dividend yield of 2% [3] - The dividend yield of the Banks - Southeast industry is 2.38%, while the S&P 500's yield is 1.49% [3] - The company's annualized dividend of $0.44 has increased by 7.3% from the previous year [4] - Over the last 5 years, Investar has raised its dividend 4 times, averaging an annual increase of 11.29% [4] - The current payout ratio is 20%, indicating that the company pays out 20% of its trailing 12-month EPS as dividends [4] Earnings Growth - The Zacks Consensus Estimate for 2025 earnings is $1.93 per share, reflecting a year-over-year growth rate of 2.12% [5] - Earnings growth appears solid for Investar in the current fiscal year [5] Investment Considerations - Investar is viewed as a compelling investment opportunity due to its strong dividend profile [6] - The stock holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [6]

Earnings and Economic Outlook - Second quarter earnings are on pace for 10% year-on-year growth, with double-digit growth likely by year-end [2] - Expectation of softening in the economy in the second half of the year, but not recessionary [2] - Anticipation of lower interest rates by the Federal Reserve in 2026, coupled with a potential tax bill kicking in next year, supporting continued earnings growth [2] Federal Reserve Policy - Market overreacted to the possibility of three rate cuts this year; one to two cuts are more likely [3] - Cooling labor market data, with revisions substantially lower for the past two months, supports the potential for the Fed to move rates towards a neutral level of around 35% [4][5] - Expectation that Jerome Powell will signal a potential rate cut and indicate that a 50 basis point rate cut is unlikely [6] Investment Strategy and Technology - Tech and AI sectors have exceeded expectations in terms of capex, data center spending, revenue, and earnings [9] - Investors should have exposure to the long-term secular story in AI and technology [10] - Expectation that sectors benefiting from productivity gains, such as healthcare, industrials, and financial services, will participate in the AI and technology growth [10] - AI and technology are expected to help reduce inflationary pressures by making costs more effective [12] - Margin expansion is anticipated in 2026, partly driven by the AI story [13] - Technology will be used to supplement labor, a trend expected to start next year and continue in the years ahead [15]